RxDoctor Payments Data

Shannon Routhouska, MD

Dermatology · Rochester, NYNPI 1720282163

Payments from drug & device makers

$1,850in general payments, 2019–2025

Across 64 payments — averaging $28.90 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$472
  • Sanofi$337
  • AbbVie$296
  • Pfizer$250
  • Regeneron Healthcare Solutions, Inc.$151
  • Amgen$99
  • plus $244 from 8 others

What the payments were for

  • Food & beverage$1,39375%
  • Education$45725%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,850 in reported general payments places this provider in the 45th percentile of 1,151 dermatology providers in New York.

See all dermatology providers in New York

Medicare billing

Part B allowed, 2024
$86,104
Medicare patients
366
Services billed
1,529

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Humira(Cf) PenAdalimumab39$570,486
Skyrizi PenRisankizumab-Rzaa15$312,064
Dupixent PenDupilumab60$274,508
Taltz AutoinjectorIxekizumab27$178,753
RinvoqUpadacitinib15$121,714
AdbryTralokinumab-Ldrm23$83,256
Cosentyx Sensoready (2 Pens)Secukinumab11$80,683
OtezlaApremilast11$50,458
Clobetasol Propionate217$9,558
SoolantraIvermectin13$9,217
Metronidazole154$7,163
Tacrolimus38$5,460
Ciclopirox99$4,473
Calcipotriene20$4,431
Ivermectin14$3,568

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRinvoq$296$121,71415 claims
AmgenOtezla$99$50,45811 claims
Galderma Laboratories, L.p.Soolantra$13$9,21713 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 1,151 dermatology providers in New York.

Other dermatology in Rochester

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →